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Abstract G protein-coupled receptor kinase 2 (GRK2) plays a
key role in determining the rate and extent of G protein-coupled
receptor (GPCR) desensitization and resensitization. Recent
data indicate that GRK2 activity, subcellular distribution and
expression are tightly regulated. The important physiological
function of GRK2 as a modulator of the efficacy of GPCR signal
transduction systems is exemplified by its relevance in cardio-
vascular physiopathology as well as by its emerging role in the
regulation of chemokine receptors.
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The cellular responses to agonists acting through G protein-
coupled receptors (GPCRs) are usually rapidly attenuated, a
process that is critical to prevent the uncontrolled stimulation
of cells. Mechanisms of attenuation include removal of ago-
nist from the extracellular £uid and receptor desensitization,
endocytosis and down-regulation. Receptor phosphorylation
by speci¢c G protein-coupled receptor kinases (GRKs) plays a
key role in triggering rapid desensitization [1^5]. The GRK-
mediated phosphorylation of the agonist-occupied receptor
promotes the binding of a member of the family of uncou-
pling proteins termed L-arrestins, resulting in the uncoupling
of the receptor from G proteins.
There are six known members of the GRK family, GRK1
to GRK6, which share a number of structural and functional
similarities [2,4,6,7] and di¡er in both an N-terminal domain
of largely unknown function, and a C-terminal domain of
variable length, that contains speci¢c determinants for mem-
brane attachment. GRK2 is a ubiquitous member of the GRK
family which has been shown to phosphorylate a variety of
GPCRs (see [3] for a recent review). Recent evidence indicates
that, besides promoting receptor uncoupling, GRK2 would
also directly participate in GPCR sequestration, thus trigger-
ing receptor dephosphorylation and recycling [5,8^10]. More-
over, GRK2 and L-arrestin have been suggested to participate
in the regulation of the mitogen-activated protein kinase cas-
cade by GPCR [11]. This fact, together with the recently re-
ported phosphorylation of tubulin by GRK2 [12], further
stresses the relevance of this kinase in GPCR signaling. This
review focuses on the mechanisms of regulation of GRK2
activity and subcellular distribution, as well as on some phys-
iological processes in which an important participation of this
kinase has recently been unveiled.
1. Modulation of GRK2 subcellular distribution and activity
GRK2 activity and subcellular localization appear to be
subject to complex regulatory processes. Although GRK2
was initially described as a soluble, cytosolic enzyme that
transiently translocates to the plasma membrane upon recep-
tor activation, recent data indicate that several GRK2 pools
exist inside the cells: cytosolic, plasma membrane-bound and
microsomal membrane-bound [11,13^15]. Interestingly,
GRK2 activity is regulated upon interaction with several pro-
teins and lipids in the three cellular pools.
GRK2 translocation to the plasma membrane seems to be
facilitated by its interaction with free GLQ subunits released
upon receptor activation, as well as with the agonist-occupied
form of the receptor itself [2,6]. A recent report has shown
that these mechanisms occur in intact cells, and that there is a
selective interaction of speci¢c pools of GLQ subunits with
receptors and GRKs [16]. The interaction with GLQ subunits
does not only facilitate the translocation of the kinase to the
plasma membrane, but synergistically enhances the agonist-
dependent phosphorylation of the receptor [17,18]. The GLQ
binding domain is located in the C-terminal portion of the
kinase (residues 546^670), and partially overlaps with a pleck-
strin homology (PH) domain (residues 553^651) which N-ter-
minal portion has been suggested to mediate the interaction of
GRK2 with phosphatidyl inositol 4,5-bisphosphate (PIP2) and
other phospholipids. The binding of GRK2 to both GLQ sub-
units and PIP2 would be needed for full kinase activation
[17,18]. However, the exact mechanism by which GRK2 trans-
locates to the plasma membrane is not fully understood and
deserves further investigation.
On the other hand, a signi¢cant amount of GRK2 is asso-
ciated to internal microsomal membranes by means of electro-
static interactions between an N-terminal region of the kinase
(residues 88^145) and an unknown protein which is an inte-
gral component of the microsomal membrane [13,14]. Most
interesting is the fact that the interaction of GRK2 with the
unidenti¢ed anchoring protein leads to inactivation of the
bound kinase. Although GLQ subunits do not play a prefer-
ential role in determining GRK2 subcellular distribution
under basal conditions [15], microsome-bound GRK2 activity
can be enhanced by stimulation of endogenous heterotrimeric
G proteins [14]. Nevertheless, the role of the GRK2 pool in
internal membranes still remains unclear. An interesting hy-
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pothesis is that this pool acts as a reservoir for its transloca-
tion to the plasma membrane upon receptor activation. Alter-
natively, or in addition, it may also re£ect other cellular func-
tions of GRK2. In this context, recent data have shown that
GRK2 colocalizes in endosomes with L-adrenergic receptors
during agonist-induced receptor internalization [10], and that
the kinase cellular complement determines the rate and extent
of GPCR desensitization and resensitization [5,8,19]. Further-
more, GRK2 is also associated with other cellular structures,
such as microtubules puri¢ed from bovine brain, and is able
to phosphorylate tubulin ([12] and C. Murga and F. Mayor,
Jr., unpublished observations). A better understanding of the
distribution and tra⁄c of GRK2 between these di¡erent sub-
cellular locations would help to ascertain its di¡erent cellular
roles.
Other mechanisms appear to contribute to the regulation of
GRK2 activity. Calmodulin has been reported to inhibit ago-
nist-dependent phosphorylation of muscarinic receptors or
rhodopsin by GRK2 in a Ca2-dependent manner [20,21].
Recent studies suggest that calmodulin may also inhibit
GRK activity in a Ca2-independent manner [22]. In addition,
the cytosolic phosphoproteins phosducin and phosducin-like
proteins inhibit GRK2 activity towards GPCR, probably by
competing with GRK2 for free GLQ subunits [23]. Finally, it
has recently been shown that GRK2 and GRK5 activities are
regulated by PKC phosphorylation [24^26]. Phosphorylation
of GRK2 by PKC leads to an activation of the kinase, prob-
ably by increasing GRK2 ability to bind to the plasma mem-
brane. It is tempting to suggest that phosphorylation by other
unidenti¢ed kinases or interaction with additional proteins
may also alter GRK2 functions. In fact, our laboratory has
recently identi¢ed a cytosolic factor able to modulate GRK2
activity (A. Ruiz-Gomez, A. Elorza and F. Mayor, Jr., in
preparation). In summary, regulation of GRK2 activity and
subcellular distribution is a complex process that involves the
interaction of the kinase with anchoring proteins in several
cellular membranes, as well as the modulation of its activity
by targeting, phosphorylation or binding to multiple proteins
in di¡erent cellular pools (see Fig. 1). The occurrence of such
complex regulatory mechanisms is consistent with a key role
of GRK2 in GPCR signaling processes.
2. Physiological functions
Recent reports suggest that the extent of agonist-mediated
desensitization and sequestration of GPCR depends on the
cellular content of GRKs and L-arrestins [19,27]. Therefore,
in a given tissue, di¡erent GPCRs would desensitize/resensi-
tize at di¡erent rates, depending on the particular receptor/
GRK/arrestin expression pattern. GRK2 is ubiquitously ex-
pressed, with higher levels found in brain, leukocytes, heart
and spleen, followed by lung and kidney [7]. Such expression
pattern suggests a particularly important role of GRK2 in
neurotransmission, cardiovascular function and immune and
in£ammatory responses.
2.1. GRK2 and cardiovascular function
GPCRs mediate the actions of messengers such as catechol-
amines, endothelins or angiotensin, which are key regulators
of cardiovascular functions and are involved in cardiovascular
development and in the control of growth and remodeling of
cardiovascular cells. GRK2 has been shown to modulate sev-
eral types of adrenergic, angiotensin and endothelin receptors
[3,5]. Such receptor systems are also important pharmacolog-
ical targets in the management of chronic heart failure, angina
pectoris or hypertension, and desensitization of GPCR is clin-
ically relevant in several cardiovascular diseases [28^30].
An important feature of heart failure is reduced L-adrener-
gic-stimulated cyclase activity, due to both diminished L1 re-
ceptor number (down-regulation) and impaired receptor func-
tion (uncoupling) [31]. Interestingly, mRNA levels for GRK2
as well as kinase activity are increased almost three-fold in the
ventricles of congestive heart failure patients [5,32]. GRK2
levels are also altered in mouse models of cardiac hypertrophy
[33], suggesting that GRK2 is an important factor underlying
alterations of adrenergic signaling in such situation [31,34].
An increased GRK2 activity has also been found in hyper-
tensive patients which show reduced L2AR responsiveness
[35]. Consistent with a key role for GRK2 in cardiac function,
cardiac contractility can be decreased or enhanced in trans-
genic mice overexpressing GRK2 or GRK2 inhibitor con-
structs, respectively [36]. Increased GRK activity seems to
be an early step that preceded changes in the expression of
adenylyl cyclase isoforms also taking place in heart failure
[37]. Moreover, the disruption of the GRK2 gene results in
marked myocardial hypoplasia and embryonic death in mice,
indicating a crucial role for this kinase in cardiac cell growth
and di¡erentiation [38]. It is important to note that although
GRK2 and GRK3 share a high degree of homology and over-
lapping patterns of substrate speci¢city ‘in vitro’, the disrup-
tion of the GRK3 gene allows for normal embryonic and
postnatal development and only leads to the loss of odorant
receptor desensitization [39]. To ascertain the mechanisms and
signals governing the expression and activity levels of GRKs
and arrestins in cardiovascular cells may prove important for
understanding some key aspects of cardiovascular physiopa-
thology.
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Fig. 1. Modulation of GRK2 activity and subcellular distribution.
Upon G protein-coupled receptor (GPCR) activation by ligands (L),
GRK2 translocates to the plasma membrane, where its activity is
regulated by interaction with the activated GPCR, GLQ subunits of
G proteins and inositol phospholipids (PIP2). Phosducin (PhD) can
inhibit GLQ-mediated modulation. GRK2 participates in GPCR in-
ternalization and may phosphorylate other substrates di¡erent from
activated GPCR. Calmodulin, PKC phosphorylation and the inter-
action of GRK2 with a microsomal anchoring protein participate in
the modulation of GRK2 activity and subcellular localization. See
text for details.
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2.2. GRKs and desensitization of chemokine receptors
Chemokine receptors cause chemotactic and pro-adhesion
e¡ects in leukocytes in response to locally produced chemo-
attractants. The responsiveness of the cells to chemoattrac-
tants is transient and results in rapid receptor desensitization.
The rapid modulation of signaling is likely to be important in
maintaining the ability of leukocytes to sense the gradient of
chemoattractant and in the regulation of the in£ammatory
response [40,41]. Therefore, the biochemical relationship be-
tween receptor-mediated activation, desensitization and resen-
sitization appears to be important in the response to injury
and infection.
Chemokines promote cellular signaling by interaction with
di¡erent GPCRs, several of which have been recently identi-
¢ed as cofactors in the internalization of the human immuno-
de¢ciency virus [42]. Molecular cloning studies have identi¢ed
several groups of chemokines. The best known are the C-X-C
and CC-chemokines, according to the position of the con-
served cysteine residues. Among the C-X-C chemoattractants
are the peptides IL-8, complement content C5a and N-formyl-
ated peptides (e.g. fMLP), which are predominantly chemo-
tactic for neutrophils. The C-C family, which includes macro-
phage in£ammatory protein 1a and 1b (MIP-1a and -1b),
monocyte chemotactic protein 1 (MCP-1) and RANTES
(regulated upon activation, normal T expressed and secreted),
is chemotactic predominantly for monocytes and lymphocyte
subsets [43].
The functional importance of phosphorylation by GRKs in
chemokine receptor desensitization has been recently reported.
In the case of IL-8 receptors, it has been shown that ligand
binding to both IL-8RA and IL-8RB results in rapid receptor
phosphorylation in its C-terminal domain, desensitization and
sequestration [44^46]. The results are consistent with the ago-
nist-dependent and agonist-independent phosphorylation of
the receptor by GRK proteins and protein kinase C, respec-
tively. The receptors for fMLP and C5a have also been dem-
onstrated to become rapidly phosphorylated in a similar proc-
ess [47,48]. In the case of the formyl peptide receptor,
Prossnitz et al. [49] showed that GRK2 was able to phospho-
rylate its C-terminal cytoplasmic tail, whereas GRK3 had 50%
of the activity of GRK2, and GRK5 and GRK6 had no
detectable e¡ect. Recently, the signaling and internalization
of the CXCR4 receptor was demonstrated to be regulated
by both receptor phosphorylation-dependent and -independ-
ent mechanisms [50].
A more direct involvement of GRK proteins has been dem-
onstrated for CC-chemokine receptor desensitization. The
CCR-2B receptor is rapidly phosphorylated and internalized
upon MCP-1 induction in monocytes and transfected
HEK293 cells. Co-expression of CCR-2B in Xenopus oocytes
with GRK3, but not GRK2, speci¢cally blocked receptor ac-
tivation by MCP-1 [51]. More interestingly, a direct interac-
tion between GRKs and this chemokine receptor has recently
been reported under physiological circumstances, by showing
co-immunoprecipitation of the ligand-activated CCR-2 recep-
tor and GRK2 in monocytes [52]. In these cells, GRK2 trans-
locates to membranes upon MCP-1 stimulation, leading to
CCR-2 receptor phosphorylation. One important ¢nding
was the fact that GRK2 forms a multimolecular complex
with the activated receptor and L-arrestin [52]. The CCR-2B
receptor expressed in HEK293 cells can also be phosphoryl-
ated and desensitized by the GRK3 besides GRK2. Unlike the
CCR-2 receptor, CCR-5 was desensitized and phosphorylated
only following overexpression of GRKs in HEK293 cells [53].
CCR-5 could be phosphorylated by overexpression of GRK-
2, -3, -5 or -6 in this cell type, but it is still not known which
GRK regulates the CCR-5 in lymphocytes under physiologi-
cal conditions. In addition, CCR-5 internalization in HEK293
cells was only observed upon overexpression of L-arrestin 1 or
2. This constitutes another example about how the biochem-
ical complements of signaling molecules in given cell lines
might determine the selectivity of the signal transduction
pathways. The fact that other chemokine receptors, like the
CCR-2, are desensitized in HEK293 cells by endogenous
GRKs may be explained by a lower a⁄nity of the CCR-5
receptor for these kinases. Interestingly, the extent of desensi-
tization of the CCR-2 receptor is nevertheless diminished in
HEK293 cells with respect to monocytes, which contain high-
er levels of GRK2 [52]. These observations raise the possibil-
ity that the CC-chemokine receptors require high levels of
expression of GRKs and L-arrestins to be e¡ectively desensi-
tized and internalized, consistent with the pattern of expres-
sion of these proteins in leukocytes. They also indicate that
variation in the complement of the GRKs may be an impor-
tant physiological mechanism in determining the speci¢city of
regulation of certain GPCRs [53].
Some CC-chemokine receptors, like the CCR-5, act as a co-
receptor required for HIV-1 internalization [42]. Although
some reports have shown that this process can occur in ab-
sence of desensitization and internalization of the chemokine
receptor [54,55], more experiments are needed to assess the
role of GPCR signalling, modulation and down-regulation
in the infection process. On the other hand, it has recently
been shown that neither phosphorylation of C-tail serines or
threonines nor internalization of chemokine receptors a¡ects
chemotaxis measured in an unidirectional assay [56,57].
Therefore, the cells seem to migrate in a process that does
not require continuous modulation at the level of receptor.
However, whether receptor internalization/desensitization are
important for a migrating cell to change direction deserves
further research.
In summary, GRK2 appears to have a key role in the de-
sensitization of a variety of chemokine receptors. Although it
will be necessary to perform more in vivo experiments to
ascertain which GRKs are responsible for the desensitization
of each particular chemokine receptor in leukocytes, modula-
tion of GRK2 activity and expression emerges as a new target
to regulate cell responses to chemokines.
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